甲状腺内钙化行彩超检查对乳头甲状腺癌患者的诊断应用

Application of colour dopplar ultrasound examination of thyroid calcification on diagnosis of papillary thyroid carcinoma

目的探讨甲状腺内钙化行彩超检查对乳头甲状腺癌患者的诊断价值。方法收集2014年1月至2016年12月商丘市中心医院收治的60例甲状腺内钙化患者,术前进行彩色多普勒超声检查,术后进行病理学检查。对检查结果进行分析研究。结果本组60例患者中,良性病变32例,其中微小钙化者8例(25%),粗大钙化者24例(75%);恶性病变28例,微小钙化者20例(71%),粗大钙化者8例(28%)。经比较分析结果,甲状腺良恶性病变患者比较显示甲状腺内钙化的发生率更高,差异具有统计学意义(P<0.05)。通过患者术后病理检查可知,28例微小钙化患者中,19例(67.85%)有乳头状甲状腺癌,32例粗大钙化患者中,4例(11.76%)有乳头状甲状腺癌。说明,使用彩超检查,粗大钙化患者发生乳头状甲状腺癌的几率低于微小钙化患者,差异具有统计学意义(P<0.05)。结论彩超检查可以使患者甲状腺内的钙化情况更好的显现,为患者确诊乳头甲状腺癌提供了依据。

Objective To explore the value of colour dopplar ultrasound of thyroid calcification on the diagnosis of papillary thyroid carcinoma. Methods Collected in January 2014 to December 2016 in shangqiu of 60 patients with thyroid calcification within the center＇ s hospitals, on preoperative color doppler ultrasound examination, postoperative pathologi- cal examination. Analyzed the result of the inspection. Results All 60 cases patients, 32 cases of benign pathological changes, the tiny calcification in 8 cases （25%） , rough calcification, 24 cases （75%） ; 28 cases of malignant change, the tiny calcification 20 cases （71%）, rough calcification in 8 cases （28%）. By the comparative analysis of the re- suits, comparing patients with thyroid benign and malignant lesions showed higher incidence of calcification in thyroid, statistically significant difference （P 〈 0. 05）. By patients with postoperative pathologic examination, the tiny calcifica- tion in patients with 28 cases, 19 cases （67.85 % ） had papillary thyroid carcinoma and 32 patients with bulky calcifica- tion, 4 cases （ 11.76% ） had papillary thyroid cancer. Instructions, the use of colour to exceed check, bulky calcifica- tion in patients with the chance of papillary thyroid cancer is lower than the tiny calcification patients, statistically signif- icant difference （P 〈 0.05 ）. Conclusion Colour dopplar ultrasound can make appeared in the patients with thyroid calcification, provide the basis for diagnosis of papillary thyroid cancer patients.